Pharmaceutical

FDA denies approval for Astellas’ investigational gastric cancer drug

Approval for zolbetuximab was quashed after the FDA found deficiencies in the company’s third-party manufacturing.

Jan 9, 2024 - 18:00
FDA denies approval for Astellas’ investigational gastric cancer drug
Approval for zolbetuximab was quashed after the FDA found deficiencies in the company’s third-party manufacturing.
Read the original article

Tags:

Previous Article

No pain data yet from Vertex, and sky high deal expectations at JPM 2024

Next Article

Zealand raises DKr1.45bn to advance obesity pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Patients want test results now, and radiologists need time to explain. Can they meet in the middle?

STAT+: Patients want test results now, and radiologists...

Dec 1, 2023

FDA approves Analog and Dipharma’s ANDA for nitisinone capsules

FDA approves Analog and Dipharma’s ANDA for nitisinone ...

Jun 1, 2023

FDA expert panel endorses idea of removing a component from flu vaccine

FDA expert panel endorses idea of removing a component ...

Oct 6, 2023